相关实验视频

Updated: Jul 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

在子宫内膜癌中使用莱特zole/abemaciclib/LY3023414的组合芳酶,CDK4/6和PI3K阻断

Panagiotis A Konstantinopoulos¹, Niya Xiong¹, Carolyn Krasner¹

¹Dana-Farber Cancer Institute, Boston, MA, USA.

Gynecologic oncology reports

|March 1, 2024

概括

结合PI3K和CDK4/6抑制剂显示出治疗耐药子宫内膜癌的潜力. 一位患有多个突变的患者对这种新型组合疗法获得了部分反应.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
泌尿生殖系统癌症是什么

背景情况:

临床前数据表明,结合PI3K和CDK4/6抑制剂可以克服癌症中对激素治疗的耐药性.
子宫内膜癌 (EC) 通常会对标准治疗产生抗性,需要新的治疗策略.
针对PI3K/AKT/mTOR途径和循环素依赖激酶 (CDK) 是EC治疗的一个有前途的方法.

研究的目的:

评估结合abemaciclib (一种CDK4/6抑制剂),莱特和LY3023414 (一种PI3K/mTOR抑制剂) 在复发性子宫内膜癌的疗效和安全性.
探索这种组合疗法的潜力,以克服EC中的抵抗机制.

主要方法:

一项临床研究评估了abemaciclib,莱特和LY3023414在复发性子宫内膜癌患者中的组合.
这项研究涉及一小群患者,原因是LY3023414发育的早期终止.
对患者样本进行了基因组分析,以确定相关突变.

主要成果:

该研究在仅有5名患者接受协议治疗后过早终止.
一名患有复发性子宫内膜体EC的患者,患有AKT1,CTNNB1和ESR1热点突变,实现了部分反应.
这位患者之前曾经接受过莱特醇/埃弗洛利斯治疗,这表明该组合在耐药性疾病中具有潜在活性.

结论:

阿贝马西克利布,莱特和LY3023414的组合在一个先前接受过大量治疗的患有晚期子宫内膜癌的患者中显示出初步活性.
这一案例凸显了针对PI3K和CDK4/6通路的潜力,以克服EC中对激素治疗的抗性.
需要对PI3K和CDK4/6抑制组合进行进一步的研究,尽管LY3023414的开发已经停止.

关键词:

阿贝马西克利布 (Abemaciclib) 是一个女性.抑制芳香酶的抑制.它可以抑制CDK4/6的抑制.这是子宫内膜癌的癌症.LY302341414 的时间.抑制PI3K的抑制作用

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...